Global Market Insights: Penny Stocks To Watch In February 2026

As global markets navigate a mixed landscape, with large-cap technology stocks facing challenges and small-cap and value-oriented segments gaining traction, investors are seeking new opportunities. Penny stocks, while often overlooked, present a unique chance to explore growth potential in smaller or newer companies. Despite being seen as an outdated term, penny stocks remain relevant for those looking to uncover hidden value; we've identified three that combine strong financial health with promising prospects.

Top 10 Penny Stocks Globally

Name	Share Price	Market Cap	Rewards & Risks
Critical Holdings Berhad (KLSE:CHB)	MYR0.81	MYR301.11M	✅ 4 ⚠️ 1 View Analysis >
Cloudpoint Technology Berhad (KLSE:CLOUDPT)	MYR0.57	MYR303.01M	✅ 4 ⚠️ 1 View Analysis >
Lever Style (SEHK:1346)	HK$1.40	HK$865.93M	✅ 4 ⚠️ 1 View Analysis >
Foresight Group Holdings (LSE:FSG)	£4.125	£470.77M	✅ 5 ⚠️ 0 View Analysis >
TK Group (Holdings) (SEHK:2283)	HK$2.48	HK$2.05B	✅ 4 ⚠️ 1 View Analysis >
Angler Gaming (NGM:ANGL)	SEK3.60	SEK269.95M	✅ 4 ⚠️ 2 View Analysis >
Yangzijiang Shipbuilding (Holdings) (SGX:BS6)	SGD3.31	SGD13.03B	✅ 5 ⚠️ 1 View Analysis >
Integrated Diagnostics Holdings (LSE:IDHC)	$0.635	$369.14M	✅ 4 ⚠️ 2 View Analysis >
Scott Technology (NZSE:SCT)	NZ$2.74	NZ$232.1M	✅ 4 ⚠️ 1 View Analysis >
BTG Consulting (AIM:BTG)	£1.19	£191.51M	✅ 6 ⚠️ 1 View Analysis >

Click here to see the full list of 3,509 stocks from our Global Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (SEHK:1349)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. focuses on the research, development, manufacture, and sale of bio-pharmaceutical products in China with a market capitalization of approximately HK$8.21 billion.

Operations: The company generates revenue primarily from its Pharmaceuticals segment, amounting to CN¥711.63 million.

Market Cap: HK$8.21B

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has shown volatility typical of smaller stocks, with recent guidance indicating a net loss for 2025 between RMB 120 million and RMB 180 million. Despite being unprofitable, the company is debt-free with strong short-term asset coverage over liabilities. Their focus on R&D is evident, investing approximately RMB 350 million in projects like the Phase III clinical trial for Trop2-SN38 ADC to treat breast cancer. However, challenges include decreased profit margins from their LIBOd® product due to pricing adjustments and competitive pressures in centralized drug procurement.

• Jump into the full analysis health report here for a deeper understanding of Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd.
• Examine Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's past performance report to understand how it has performed in prior years.

Antengene (SEHK:6996)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Antengene Corporation Limited is a clinical-stage APAC biopharmaceutical company focused on developing novel oncology therapies in Greater China and internationally, with a market cap of HK$2.39 billion.

Operations: The company generates revenue of CN¥84.35 million from the research, development, and commercialization of pharmaceutical products.

Market Cap: HK$2.39B

Antengene Corporation Limited, with a market cap of HK$2.39 billion, is navigating the complexities of clinical-stage development with promising oncology therapies. Despite being unprofitable and having a negative return on equity, the company has reduced its losses over five years and maintains sufficient cash runway for more than two years. Recent advancements include positive clinical signals for ATG-022 in non-gastrointestinal tumors and regulatory approvals for XPOVIO® in multiple APAC regions. The seasoned management team supports strategic R&D efforts, including innovative T-cell engager platforms potentially expanding treatment options across various cancers and autoimmune diseases.

• Navigate through the intricacies of Antengene with our comprehensive balance sheet health report here.
• Learn about Antengene's future growth trajectory here.

Qinghai Spring Medicinal Resources Technology (SHSE:600381)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Qinghai Spring Medicinal Resources Technology Co., Ltd. operates in the medicinal resources sector and has a market cap of approximately CN¥1.89 billion.

Operations: Qinghai Spring Medicinal Resources Technology Co., Ltd. has not reported any specific revenue segments.

Market Cap: CN¥1.89B

Qinghai Spring Medicinal Resources Technology, with a market cap of CN¥1.89 billion, remains pre-revenue and unprofitable but has made progress by reducing losses at 6% annually over the past five years. The company benefits from a seasoned management team with an average tenure of 10.8 years and an experienced board averaging 6.2 years. Qinghai Spring is debt-free and boasts sufficient cash runway for over three years if free cash flow continues to grow historically at 51.1% per year, providing some financial stability despite its current lack of profitability. Recent events include a shareholders meeting scheduled for December 2025.

• Click here to discover the nuances of Qinghai Spring Medicinal Resources Technology with our detailed analytical financial health report.
• Review our historical performance report to gain insights into Qinghai Spring Medicinal Resources Technology's track record.

Key Takeaways

• Jump into our full catalog of 3,509 Global Penny Stocks here.
• Curious About Other Options? AI is about to change healthcare. These 107 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com